Literature DB >> 23907518

Current treatment of locoregional recurrence of melanoma.

Malcolm Hart Squires1, Keith A Delman.   

Abstract

Surgical resection is the mainstay of therapy for locoregional recurrence of melanoma and the best chance for long-term cure in patients with locoregional recurrence of melanoma. In addition to true local recurrence at the site of the primary lesion, locoregional relapse can occur as regional nodal disease or as satellite or in-transit metastases, which may be unresectable and can present significant treatment challenges. Options for unresectable locoregional recurrence include regional hyperthermic isolated limb perfusion or isolated limb infusion, topical therapies, intralesional injection therapies, laser ablation, radiation therapy, and systemic therapy. Given the risk of further relapse and the negative impact on prognosis and overall survival after locoregional recurrence of melanoma, most patients should be considered for aggressive locoregional therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907518     DOI: 10.1007/s11912-013-0333-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  81 in total

1.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

2.  Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation.

Authors:  Daniel T Chang; Robert J Amdur; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-12       Impact factor: 7.038

3.  Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.

Authors:  Brian Badgwell; Yan Xing; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2007-08-01       Impact factor: 5.344

4.  Chemoablation of metastatic melanoma using intralesional Rose Bengal.

Authors:  John F Thompson; Peter Hersey; Eric Wachter
Journal:  Melanoma Res       Date:  2008-12       Impact factor: 3.599

Review 5.  Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion.

Authors:  Alessandro Testori; Cornelis Verhoef; Hidde M Kroon; E Pennacchioli; Mark B Faries; Alexander M M Eggermont; John F Thompson
Journal:  J Surg Oncol       Date:  2011-09       Impact factor: 3.454

6.  Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.

Authors:  Marcello Pace; Riccardo Gattai; Erminia M Mascitelli; Luigi Millanta
Journal:  J Surg Oncol       Date:  2011-06-30       Impact factor: 3.454

7.  Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases.

Authors:  Carlo Riccardo Rossi; Sandro Pasquali; Simone Mocellin; Antonella Vecchiato; Luca Giovanni Campana; Pierluigi Pilati; Antonio Zanon; Donato Nitti
Journal:  Ann Surg Oncol       Date:  2010-04-29       Impact factor: 5.344

Review 8.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

9.  Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.

Authors:  Edward L Jones; Teresa S Jones; Nathan W Pearlman; Dexiang Gao; Robert Stovall; Csaba Gajdos; Nicole Kounalakis; Rene Gonzalez; Karl D Lewis; William A Robinson; Martin D McCarter
Journal:  JAMA Surg       Date:  2013-05       Impact factor: 14.766

10.  Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.

Authors:  Travis B Kidner; Donald L Morton; Delphine J Lee; Mary Hoban; Leland J Foshag; Roderick R Turner; Mark B Faries
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

View more
  6 in total

1.  Effect of adipose-derived stem cell-conditioned medium on the proliferation and migration of B16 melanoma cells.

Authors:  Ju-Hee Lee; Chul Hong Park; Kwang-Hoon Chun; Soon-Sun Hong
Journal:  Oncol Lett       Date:  2015-06-10       Impact factor: 2.967

Review 2.  Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.

Authors:  Amy A Mrazek; Celia Chao
Journal:  Surg Clin North Am       Date:  2014-08-05       Impact factor: 2.741

Review 3.  In-transit metastatic cutaneous melanoma: current management and future directions.

Authors:  Ayushi Patel; Michael J Carr; James Sun; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2021-05-17       Impact factor: 5.150

4.  Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis.

Authors:  S Morteza Seyed Jafari; Christina Wiedmer; Simone Cazzaniga; Živa Frangež; Maziar Shafighi; Helmut Beltraminelli; Benedikt Weber; Hans-Uwe Simon; Robert E Hunger
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

5.  Two-team-approached free flap reconstruction for plantar malignant melanoma: An observational (STROBE-compliant) trial.

Authors:  Jun Hyeok Kim; Chae Rim Lee; Hyo Jeong Kwon; Deuk Young Oh; Young-Joon Jun; Jong Won Rhie; Suk-Ho Moon
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

6.  Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy.

Authors:  Sophia Haywood; Jennifer Garioch; Arjun Ramaiya; Marc Moncrieff
Journal:  Ann Surg Oncol       Date:  2020-06-15       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.